VTVT vs. CMRX, ASRT, ONCY, GNLX, PRPH, RVPH, ACRS, AFMD, IFRX, and MIST
Should you be buying vTv Therapeutics stock or one of its competitors? The main competitors of vTv Therapeutics include Chimerix (CMRX), Assertio (ASRT), Oncolytics Biotech (ONCY), Genelux (GNLX), ProPhase Labs (PRPH), Reviva Pharmaceuticals (RVPH), Aclaris Therapeutics (ACRS), Affimed (AFMD), InflaRx (IFRX), and Milestone Pharmaceuticals (MIST). These companies are all part of the "pharmaceutical preparations" industry.
Chimerix (NASDAQ:CMRX) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.
vTv Therapeutics has a net margin of 0.00% compared to vTv Therapeutics' net margin of -25,337.96%. Chimerix's return on equity of 0.00% beat vTv Therapeutics' return on equity.
45.4% of Chimerix shares are held by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are held by institutional investors. 10.0% of Chimerix shares are held by company insiders. Comparatively, 1.7% of vTv Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Chimerix has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500. Comparatively, vTv Therapeutics has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500.
Chimerix received 35 more outperform votes than vTv Therapeutics when rated by MarketBeat users. Likewise, 64.01% of users gave Chimerix an outperform vote while only 57.83% of users gave vTv Therapeutics an outperform vote.
Chimerix currently has a consensus price target of $8.00, suggesting a potential upside of 709.72%. Given vTv Therapeutics' higher possible upside, equities research analysts clearly believe Chimerix is more favorable than vTv Therapeutics.
vTv Therapeutics has higher revenue and earnings than Chimerix. vTv Therapeutics is trading at a lower price-to-earnings ratio than Chimerix, indicating that it is currently the more affordable of the two stocks.
In the previous week, Chimerix had 32 more articles in the media than vTv Therapeutics. MarketBeat recorded 32 mentions for Chimerix and 0 mentions for vTv Therapeutics. vTv Therapeutics' average media sentiment score of 0.17 beat Chimerix's score of 0.00 indicating that Chimerix is being referred to more favorably in the media.
Summary
Chimerix beats vTv Therapeutics on 13 of the 17 factors compared between the two stocks.
Get vTv Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VTVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
vTv Therapeutics Competitors List
Related Companies and Tools
